| Filed On | Filing |
|---|---|
| 06 Nov 2026 | SCHEDULE 13G/A |
| 04 Nov 2026 |
Form 4: Epstein David R, Director
Sold 370 shares ($27.5K) |
| 04 Nov 2026 |
Form 4: Fukushima Ryan, CEO, Data
Received 100,000 shares as a grant or award · Sold 80 shares ($5.94K) |
| 02 Nov 2026 | 144 |
| 02 Nov 2026 | 10-Q |
| 02 Nov 2026 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
CHICAGO, November 2, 2026 — Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today reported financial results for the quarter ended September 30, 2026. |
| 29 Oct 2026 |
Form 4: Lefkofsky Eric P, Director
Sold 250,000 shares ($17.6M) |
| 28 Oct 2026 | SCHEDULE 13G/A |
| 27 Oct 2026 | 144 |
| 23 Oct 2026 |
8-K: Other Events
On October 23, 2026, Tempus AI, Inc. (“Tempus”) announced that it had entered into a series of agreements with Bristol-Myers Squibb Company (“BMS”) and Pathos AI, Inc. (“Pathos”) to expand the use of Tempus’s de-identified multimodal rea... |
| 21 Oct 2026 | EFFECT |
| 21 Oct 2026 | 424B3 |
| 20 Oct 2026 | S-4/A |
| 02 Oct 2026 | S-4/A |
| 29 Sep 2026 |
Form 4: Schoenherr Thomas Edward, CEO, Diagnostics
Sold 10,281 shares ($874K) |
| 25 Sep 2026 | 144 |
| 24 Sep 2026 |
Form 4: Lefkofsky Eric P, Director
Sold 250,000 shares ($19.4M) |
| 22 Sep 2026 | 144 |
| 18 Sep 2026 |
Form 4: Lefkofsky Eric P, Director
Sold 200,000 shares ($16.1M) |
| 18 Sep 2026 |
Form 4: Bartolucci Ryan M, Chief Accounting Officer
Sold 7,062 shares ($530K) |
Loading...